key: cord-0933104-8dshs1tu authors: Cruz, Cintia; White, Nicholas J. title: COVID-19 chemoprevention date: 2021-04-24 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2021.04.045 sha: c96761143e51628bd69bdc5d48d85d4199893f0b doc_id: 933104 cord_uid: 8dshs1tu nan interventions were vitamin C (500mg once daily), zinc and vitamin C (40/250mg twice daily), povidone-iodine throat spray (three times daily; equivalent to 8.1mg iodine/month), and hydroxychloroquine (400mg salt loading dose then 200mg /day) all given for six weeks, and ivermectin (200µg/kg) which was given only once. The study primary end point was a SARS-CoV2 infection diagnosed either by nasopharyngeal swab qPCR or by seroconversion. The six week trial enrolled 3,037 men (mean age 33 years), most of whom were from India and Bangladesh. Unfortunately the hydroxychloroquine arm had strict cardiovascular exclusion criteria imposed because of safety concerns raised by the now retracted paper by Mehra et al (one of many indirect scientific casualties of this fabricated research) (3) . As a result, this arm was significantly smaller than the other arms. The overall attack rate was high; 55.4% (1,681 of 3,037) of the men became infected, but none needed hospitalization, and none died. In a logistic regression analysis, with adjustment for clustering, the attack rate in the hydroxychloroquine and the povidone-iodine throat spray groups was reduced compared with the Vitamin C only reference arm. The absolute risk reductions (98.75% confidence interval) were 21% (2-42%) in the men who received hydroxychloroquine (n=432) and 24% (7-39%) in those who took the povidoneiodine throat spray (n=735). What do the results of this carefully conducted and relatively large study mean for the prevention of COVID-19? They are certainly not conclusive, as the number of clusters per treatment arm is small, and the hydroxychloroquine arm had the additional exclusion criteria which significantly reduced the number of eligible participants. The dynamics of infection within clusters can probably never be characterized sufficiently for adequate adjustment. But the results are indicative, and they make an important contribution to the small RCT evidence base on J o u r n a l P r e -p r o o f COVID-19 chemoprophylaxis. The positive results with the povidone-iodine throat spray (4, 5) are intriguing and, although not conclusive, they certainly warrant further study given the simplicity and low cost of the spray. Zinc has had an enthusiastic and often vociferous minority following in COVID-19, but there is little evidence so far in its support (6) , and these results do not provide further encouragement. Ivermectin is widely recommended for the treatment of COVID-19, particularly in South America, without good evidence of benefit (7) . A small randomized comparison in 24 patients with acute COVID-19 showed a non-significant difference in viral clearance rates in favour of ivermectin, and several randomized comparisons have been posted before peer review, but there is really no convincing evidence reported to date (8, 9) . However, the negative result with ivermectin (t½β ~ 18 hours) in the Singapore study should not be overinterpreted as only a single relatively low dose (12mg) was administered, although there was no obvious difference in infection rates in the first week after administration. Clear evidence that ivermectin (or indeed any other putative antiviral) has a significant in-vivo antiviral effect in COVID-19 should be provided before embarking on any further investigation in prevention or treatment. The lower incidence of COVID-19 infections in the hydroxychloroquine recipients in the Singapore cluster randomized trial (2) should be viewed in the context of current World Health Organization COVID-19 therapeutic guidelines and their negative recommendations (10) (11) (12) (13) . Hydroxychloroquine has had a torrid time in COVID-19. Like many of the potential repurposing candidates it has modest activity against SARS-CoV2 and several other viruses in experimental systems. Early claims of benefit in the treatment of hospitalized patients with hydroxychloroquine, based on uncontrolled observations, were followed by premature J o u r n a l P r e -p r o o f emergency use authorizations, intense politicization, extreme views, and widespread unjustified use in treatment and potentially dangerous self-medication. Then, in May 2020, came the aforementioned highly publicized claim that hydroxychloroquine caused lethal ventricular arrhythmias in hospitalised patients (3) . The reaction from several regulatory authorities was immediate-stopping both use and study of hydroxychloroquine. The Lancet paper was subsequently shown to be fraudulent, and was retracted, but the damage was done. Recruitment to pre-(PrEP) and post exposure prophylaxis (PEP) trials plummeted, and a substantial negative perception about the safety of these drugs persists to this day. From June 2020 findings from the largest randomized controlled trials, RECOVERY and SOLIDARITY began to emerge. These provided unequivocal evidence that hydroxychloroquine treatment was ineffective in hospitalised patients (as well as good news that dexamethasone was life-saving ) (14) (15) (16) . Based largely on these inpatient studies (87.4% of studied patients were hospitalized), the WHO therapeutic guidelines in December 2020 recommended strongly against hydroxychloroquine treatment -but they extended this proscription to patients with any disease severity (10). There never was justification to recommend hydroxychloroquine for prevention or treatment outside randomized controlled trials. But the extrapolation of lack of efficacy of antiviral drugs in severe disease to uncomplicated infections was certainly not warranted by the available evidence (17) . This is because COVID-19 illness reflects a changing pathological process. Viral burdens peak early, around the onset of first symptoms. This is the time when antiviral drugs are likely to be most beneficial. Thereafter viral burdens decline and inflammatory processes dominate in those patients who deteriorate and require hospitalization, and ultimately respiratory support. In March 2021 WHO, extended their guidelines to chemoprevention. The Guidelines group strongly recommended against hydroxychloroquine in chemoprophylaxis. They further suggested that ongoing research should be "reconsidered" (i.e. discontinued). This strong recommendation was because they had concluded that there was "high certainty evidence" that hydroxychloroquine was ineffective in preventing COVID-19, and that there was "moderate certainty evidence" adverse events leading to drug discontinuation were a significant problem for hydroxychloroquine prophylaxis (11, 12) . Yet, before the Singapore trial, there had been only three published randomised controlled trials evaluating hydroxychloroquine in post-exposure prophylaxis, and only two in pre-exposure prophylaxis (another has been posted as a preprint) (18) (19) (20) . These six randomised controlled comparisons combined together enrolled 6,059 participants, but they employed varied methodologies, and they generated few endpoints. There were only 26 confirmed COVID-19 cases in total (15 out of 1,197 randomised to hydroxychloroquine, 11 out of 687 randomised to placebo) in the three PrEP trials (21) . This compares with 645 COVID-19 cases in the hydroxychloroquine and comparator (Vitamin C) groups in the Singapore study (2) . Nevertheless, despite the tiny number of endpoints in the studies they reviewed, the WHO guidelines group were somehow able to conclude with "high certainty" in their GRADE assessment (22) that hydroxychloroquine provided no useful benefit (11, 12) . In addition, their adverse events assessment contains a mistake (miscoding of one of the study results). (11, 12) . After correction the rate of discontinuations in hydroxychloroquine recipients is not significantly different to those receiving placebo (21) . This good tolerability and adherence is supported by the Singapore study. A meta-analysis of the six heterogeneous trials evaluated by the WHO guidelines, using the trial pre-specified end-points, is in the direction of protective benefit from hydroxychloroquine (23) The WHO guidelines surmised that "Mortality would be the outcome most important to individuals, followed by need for hospital admission, laboratory confirmed SARS-CoV-2 infection, and adverse effects leading to discontinuation" (11, 12) . They determined that there were no important differences in mortality in the RCTs. But there were only 13 deaths in total in the six prophylaxis trials, all from one cluster-randomised, non-blinded, post-exposure prophylaxis (PEP) trial (24) . So, without a single death in the three pre-exposure prophylaxis (PrEP) RCTs reviewed, and a highly unstable odds ratio of 0.67 for mortality in subjects allocated to hydroxychloroquine versus those who did not in the PEP RCTs (95% C.I. 0.22 to 2.05), the panel concluded somehow that this provided "high certainty evidence" that hydroxychloroquine pre-exposure prophylaxis does not reduce COVID-19 mortality (11, 12) . For the WHO's "second most important outcome" in the six RCTs, there were only 49 hospital admissions in total (20 in the PrEP RCTs; 11 hydroxychloroquine, 9 placebo). In the PrEP studies only 2 admissions were for COVID-19. There were no deaths and no hospital admissions in the Singapore study, so no further light can be cast on the strange conclusions of the WHO Guidelines. The Singapore study reported by Seet et al provides valuable information on safety, tolerability and efficacy of potential chemoprevention interventions. It confirms that chemoprophylaxis is generally acceptable. For hydroxychloroquine it emphasizes that there remains uncertainty whether or not hydroxychloroquine prophylaxis provides a modest but potentially useful protection against COVID19 infection, and that at "rheumatoid arthritis" doses, it is well tolerated. It has not been easy to conduct chemoprevention studies in COVID-19, and J o u r n a l P r e -p r o o f The Magic of Randomization versus the Myth of Real-World Evidence Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an open-label randomized trial RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a registry analysis Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Nasopharyngeal Viral Load in Patients With COVID-19: A Randomized Clinical Trial Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating patients with suspected or confirmed COVID-19 infection Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial Latin America's embrace of an unproven COVID treatment is hindering drug trials The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness World Health Organization. Therapeutics and COVID-19: living guideline A living WHO guideline on drugs for covid-19 World Health Organization. Drugs to prevent COVID-19: A WHO living guideline A living WHO guideline on drugs to prevent covid-19 Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results Guidelines should not pool evidence from uncomplicated and severe COVID-19 Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers. A Randomized Clinical Trial Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: initial results of a double-blind, placebo-controlled randomized clinical trial. PREPRINT (Version 1) available at Research Square The WHO guideline on drugs to prevent COVID-19: small numbers-big conclusions. Wellcome Open GRADE: an emerging consensus on rating quality of evidence and strength of recommendations Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19 Randomized Trial of Hydroxychloroquine for Prevention of Covid-19